rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cellectar Biosciences, Inc.

CLRB · Nasdaq

Health CareBiotechnologyNot moving yet

CLRB stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 55.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$100K
Insider sales, 12 months
$733
Officials’ trades on record
0
Institutions holding
28 (+9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$120KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months1
Buyers · sellers2 · 1
WhoDidSharesTraded
James V. CarusoChief Executive Officerbought8,680at $2.887 May 2026filed 11 May 2026
James V. CarusoChief Executive Officerbought26,040at $0.017 May 2026filed 11 May 2026
Jarrod LongcorChief Operating Officerbought8,680at $2.887 May 2026filed 11 May 2026
Jarrod LongcorChief Operating Officerbought26,040at $0.017 May 2026filed 11 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders28+9 on the quarter
New · exited13 · 4
Reported value$9.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Caligan Partners LPnew · filed 14 Aug 2026469,998$1.3M+469,998
STEMPOINT CAPITAL LPnew · filed 14 Aug 2026354,938$987K+354,938
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026327,367$910K+245,483+299.8%
SILVERARC CAPITAL MANAGEMENT, LLCnew · filed 13 Aug 2026321,728$894K+321,728
Bleichroeder LPadded · filed 13 Aug 2026288,679$803K+188,679+188.7%
Jupiter Topco LLCnew · filed 14 Aug 2026274,156$759K+274,156
Balyasny Asset Management L.P.new · filed 14 Aug 2026220,000$612K+220,000
Nantahala Capital Management, LLCnew · filed 14 Aug 2026219,998$612K+219,998
Empery Asset Management, LPnew · filed 11 Aug 2026189,605$527K+189,605
DIADEMA PARTNERS LPnew · filed 14 Aug 2026138,341$385K+138,341
30 Jun 2025 – 30 Jun 2026
162228Jun 25Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Stefan Loren Company insiderOther · last 8 Jul 20260 · 0
Andrew Gu Company insiderDirector · last 7 Jul 20260 · 0
Asher Chanan-Khan Company insiderDirector · last 7 Jul 20260 · 0
Chad J. Kolean Company insiderCFO · last 7 Jul 20261 · 0
Douglas J. Swirsky Company insiderDirector · last 7 Jul 20261 · 0
Frederick W. Driscoll Company insiderDirector · last 7 Jul 20261 · 0
James Caruso V Company insiderPresident & CEO · last 7 Jul 202611 · 1
Jarrod Longcor Company insiderChief Operating Officer · last 7 Jul 20267 · 1
John Neis Company insiderDirector · last 7 Jul 20263 · 2
Andrei Shustov Company insiderSenior Vice President, Medical · last 14 Jun 20240 · 0
Darrell Shane Lea Company insiderChief Commercial Officer · last 14 Jun 20240 · 0
Dov Elefant Company insiderChief Financial Officer · last 25 Jan 20222 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 24 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$13.2M
Free cash flowFY 2025 · to 31 Dec 2025−$23.1M

Analyst forecasts

No analyst forecasts yet.